Gujarat Themis Biosyn, a company in the Pharmaceuticals industry, reported revenue of ₹44 crore and net profit of ₹11 crore for the June 2026 quarter.
Gujarat Themis Biosyn (NSE: GUJTHEM) closed at ₹352.70 on 20 Nov 2026, down 16.6% over the past year. Its market capitalisation is ₹4,590 crore and it trades at 235.8 times earnings.
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.